Savara (SVRA)
NASDAQ:SVRA
Want to see SVRA full AI Analyst Report?
Top Page
Savara
(NASDAQ:SVRA)
Select Model
Select Model
Rating:47Neutral
Price Target:
$5.00
▼(-13.49% Downside)
Action:Reiterated
Date:05/14/26
Overall score is held down primarily by weak financial performance (no revenue, expanding losses, and substantial cash burn implying higher financing/dilution risk). Technicals are neutral with limited momentum, while valuation provides little support due to negative earnings and no dividend; the corporate event is a small positive but not a major fundamental catalyst.
Positive Factors
Rare-disease focus (PAP inhaled therapy)
A focused rare-disease strategy targeting PAP represents a durable commercial opportunity: small, underserved patient populations can provide clearer regulatory paths, orphan incentives and pricing power if clinical programs succeed, supporting a long-term specialized business model.
Negative Factors
No revenue and widening net losses
The company remains entirely pre-revenue with materially widening net losses (trend to -$129M TTM), indicating the commercial model is unproven and that ongoing operations depend on external financing until product approval and commercialization, a persistent fundamental risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Rare-disease focus (PAP inhaled therapy)
A focused rare-disease strategy targeting PAP represents a durable commercial opportunity: small, underserved patient populations can provide clearer regulatory paths, orphan incentives and pricing power if clinical programs succeed, supporting a long-term specialized business model.
Read all positive factors
Savara (SVRA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.08B
Dividend YieldN/A
Average Volume (3M)1.67M
Price to Earnings (P/E)―
Beta (1Y)1.26
Revenue GrowthN/A
EPS Growth-12.97%
CountryUS
Employees59
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.56
Shares Outstanding204,927,220
10 Day Avg. Volume1,139,092
30 Day Avg. Volume1,667,003
Financial Highlights & Ratios
PEG Ratio-1.08
Price to Book (P/B)6.60
Price to Sales (P/S)0.00
P/FCF Ratio-13.27
Enterprise Value/Market Cap0.99
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.51K
Enterprise Value/Ebitda-8.02
Forecast
1Y Price Target
$11.00Price Target Upside90.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.49
Revenue Forecast (FY)$11.00M
Savara Business Overview & Revenue Model
Company Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the...
How the Company Makes Money
null...
Savara Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -425.00K | -245.00K | -78.03M | -44.26M | -27.88M | -28.99M |
| EBITDA | -133.25M | -123.46M | -102.27M | -59.13M | -38.01M | -40.50M |
| Net Income | -129.48M | -118.84M | -95.88M | -54.70M | -38.15M | -43.01M |
Balance Sheet | ||||||
| Total Assets | 221.65M | 253.44M | 212.88M | 177.56M | 139.78M | 176.60M |
| Cash, Cash Equivalents and Short-Term Investments | 202.77M | 235.70M | 196.33M | 162.32M | 125.88M | 161.17M |
| Total Debt | 30.07M | 29.91M | 26.73M | 26.49M | 26.14M | 25.79M |
| Total Liabilities | 45.61M | 50.30M | 41.43M | 37.19M | 32.00M | 32.10M |
| Stockholders Equity | 176.04M | 203.13M | 171.45M | 140.37M | 107.78M | 144.50M |
Cash Flow | ||||||
| Free Cash Flow | -106.97M | -101.06M | -89.11M | -51.36M | -34.56M | -40.14M |
| Operating Cash Flow | -106.89M | -101.04M | -89.09M | -51.06M | -34.55M | -40.08M |
| Investing Cash Flow | -8.99M | -18.44M | -39.94M | -57.12M | 52.65M | -69.46M |
| Financing Cash Flow | 135.29M | 137.81M | 117.58M | 82.78M | 87.00K | 120.81M |
Savara Technical Analysis
Positive
5.78
Price Trends
5.51
Positive
5.76
Positive
4.55
Positive
Market Momentum
0.12
Negative
54.41
Neutral
37.90
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SVRA, the sentiment is Positive. The current price of 5.78 is above the 20-day moving average (MA) of 5.53, above the 50-day MA of 5.51, and above the 200-day MA of 4.55, indicating a bullish trend. The MACD of 0.12 indicates Negative momentum. The RSI at 54.41 is Neutral, neither overbought nor oversold. The STOCH value of 37.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SVRA.
Savara Risk Analysis
Savara disclosed 36 risk factors in its most recent earnings report. Savara reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Savara Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $590.59M | 14.38 | 147.03% | ― | 47.61% | 854.73% | |
60 Neutral | $1.81B | -5.01 | 1813.84% | ― | 107.73% | 82.33% | |
58 Neutral | $1.36B | -5.37 | -32.49% | ― | ― | -63.41% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $2.60B | -12.66 | 31.23% | ― | ― | ― | |
47 Neutral | $1.08B | -9.27 | -84.01% | ― | ― | -12.97% | |
44 Neutral | $1.21B | -7.22 | -42.90% | ― | ― | -3.83% |
* Healthcare Sector Average
SVRA
Savara
5.27
2.16
69.45%
RIGL
Rigel
31.92
12.18
61.70%
ANAB
AnaptysBio
62.19
48.59
357.38%
OLMA
Olema Pharmaceuticals
13.82
9.13
194.67%
NBTX
Nanobiotix
55.07
51.40
1400.54%
BCAX
Bicara Therapeutics Inc.
20.65
6.18
42.71%
Savara Corporate Events
Business Operations and Strategy
Savara Signs Long-Term Lease for New Headquarters
Positive
Mar 13, 2026
On March 10, 2026, Savara Inc. signed a lease with ML7 Yardley Partners, LP for about 10,795 square feet of office space at 19 W. College Avenue, Suite 200, in Yardley, Pennsylvania, with plans to relocate its headquarters there. The lease term be...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.